Compass Pathways plc will host a webinar on January 7, 2026, from 10:00 to 11:30 am ET to discuss the company's commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD). The event will feature perspectives from key opinion leaders and industry experts on the current treatment landscape and unmet needs in TRD and PTSD. The company's management will also review commercial readiness for COMP360 in TRD and outline plans for a late-stage clinical program in PTSD. The webinar will be available via live audio webcast, with a replay accessible for 30 days following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251209691887) on December 09, 2025, and is solely responsible for the information contained therein.